Stockscreener 앱 받기
411.14
0.84%
3.29
전일 마감가:
$407.85
열려 있는:
$407.07
하루 거래량:
1.69M
Relative Volume:
0.76
시가총액:
$161.94B
수익:
$42.90B
순이익/손실:
$6.52B
주가수익비율:
24.11
EPS:
17.05
순현금흐름:
$6.72B
1주 성능:
-2.05%
1개월 성능:
-1.91%
6개월 성능:
-25.45%
1년 성능:
-28.30%
1일 변동 폭
$402.81
$415.75
1주일 범위
$402.81
$431.44
52주 변동 폭
$402.81
$627.88
써모 피셔 사이언티픽 Stock (TMO) Company Profile
명칭
Thermo Fisher Scientific Inc
전화
(781) 622-1000
주소
168 THIRD AVENUE, WALTHAM, MA
TMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
411.39 | 161.94B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
195.87 | 142.65B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
493.45 | 34.79B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
109.41 | 30.62B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
154.68 | 27.00B | 15.41B | 1.37B | 2.11B | 7.50 |
써모 피셔 사이언티픽 Stock (TMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | 개시 | Scotiabank | Sector Perform |
| 2024-10-14 | 개시 | Redburn Atlantic | Buy |
| 2024-10-01 | 개시 | Stephens | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-03-18 | 재개 | Citigroup | Neutral |
| 2024-01-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-01-08 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-26 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-06 | 재개 | Citigroup | Buy |
| 2023-07-19 | 개시 | Raymond James | Outperform |
| 2023-07-19 | 재확인 | Robert W. Baird | Outperform |
| 2023-07-13 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | 재확인 | Barclays | Overweight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-10-27 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Neutral |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | 재개 | Barclays | Overweight |
| 2021-10-20 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-16 | 개시 | The Benchmark Company | Buy |
| 2021-03-18 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-12-02 | 개시 | Goldman | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-09-14 | 개시 | Morgan Stanley | Overweight |
| 2020-08-20 | 재개 | JP Morgan | Overweight |
| 2020-07-15 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2020-07-07 | 재확인 | Needham | Buy |
| 2020-04-23 | 재확인 | Needham | Buy |
| 2020-01-31 | 재확인 | Needham | Buy |
| 2020-01-22 | 개시 | Credit Suisse | Neutral |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-25 | 재확인 | Needham | Buy |
| 2019-07-16 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2019-05-30 | 개시 | Wolfe Research | Outperform |
| 2019-05-23 | 재확인 | Needham | Strong Buy |
| 2019-04-22 | 재확인 | Needham | Strong Buy |
| 2019-04-16 | 재확인 | BofA/Merrill | Buy |
모두보기
써모 피셔 사이언티픽 주식(TMO)의 최신 뉴스
Global Immunodiagnostics Market to Cross the USD 32 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 20 Years - Benzinga
Thermo Fisher Scientific Inc. (TMO): Among Billionaire Mario Gabelli’s Large-Cap Stock Picks with Huge Upside Potential - Yahoo Finance
Engineer III, Manufacturing Engineering (Waltham, MA, USA) - The Chemical Engineer Job Board
Thermo Fisher Scientific: 4 Reasons This Oversold Stock Is a Buy - Morningstar
Custom Antibody Market To Hit USD 1,230.09 Billion By 2032 | - openPR.com
High Content Screening Market Global Forecasts 2025-2030 - GlobeNewswire
Smarter protection: New Class II biological safety cabinet - Labmate Online
Thermo Fisher Scientific Inc. (TMO): Among Richard Chilton’s Stock Picks with Huge Upside Potential - Insider Monkey
Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13 - BioSpace
Thermo Fisher’s new biosafety cabinet offers improved lab safety and user experience - BioSpectrum Asia
Oversold Conditions For Thermo Fisher Scientific (TMO) - Nasdaq
Thermo Fisher Scientific Inc. stock falls Tuesday, underperforms market - MarketWatch
Thermo Fisher CEO Marc Casper to Share Strategic Updates at Major Healthcare Conference - Stock Titan
Benzyl Alcohol Market Scope: Growth, Share, Value, Size, - openPR.com
Global Raman Spectroscopy Market Is Booming So Rapidly - openPR.com
Immune Cell Engineering Market Generated Opportunities, - openPR.com
Laboratory Equipment Market Future Business Opportunities - openPR.com
Genome Engineering Market Generated Opportunities, Future - openPR.com
Is Thermo Fisher Scientific (TMO) One of the Best Falling Stocks to Buy According to Analysts? - Insider Monkey
Thermo Fisher Scientific to cut jobs at Orlando location - WFTV
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell & Exosome Therapy Manufacturing - PRWeb
THERMO FISHER SCIENTIFIC INC. SEC 10-Q Report - TradingView
Epigenetics Market Is Booming So Rapidly 2025-2032 -Illumina - openPR.com
Thermo Fisher Scientific Inc (TMO) Stock Analysis: A Closer Look at the 35.79% Potential Upside - DirectorsTalk Interviews
RoosterBio announces collaboration with Thermo Fisher to advance cell therapy manufacturing - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions To Accelerate the Development of Biologic Therapeutics - Technology Networks
RoosterBio and Thermo Fisher Scientific Agree to Collaborate to Advance Cell and Exosome Therapy Manufacturing - Genetic Engineering and Biotechnology News
Lab Automation Market Set to Witness Significant Growth - openPR.com
Thermo Fisher commits $2bn to boost US operations - The Manufacturer
Thermo Fisher Scientific (NYSE:TMO) Collaborates With RoosterBio To Advance Cell Therapy Solutions - simplywall.st
Thermo Fisher reports Q1 growth, charts a steady course for 2025 - BioProcess International
Thermo Fisher Launches Improved Biological Safety Cabinet - Contract Pharma
RoosterBio Announces Collaboration with Thermo Fisher Scientific to Advance Cell and Exosome Therapy Manufacturing - PR Newswire
Research Grade Proteins Market to Witness Massive Growth by 2032 - openPR.com
Thermo Fisher Scientific employs an enhanced platform technology - European Pharmaceutical Manufacturer
Cell Lysis Market Growth in Future Scope 2025-2032 | Thermo - openPR.com
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2025 Earnings Call Transcript - MSN
RoosterBio, Thermo Fisher Partner to Advance Cell & Exosome Therapy Manufacturing - Contract Pharma
Thermo Fisher (TMO) Target Price Reduced by Argus | TMO Stock Ne - GuruFocus
Thermo Fisher To Buy Phadia For $3.5 Billion - CHEManager Online
Argus Adjusts Price Target on Thermo Fisher Scientific to $470 From $620 - marketscreener.com
Thermo Fisher accelerates development of biologic therapeutics - BioSpectrum Asia
Thermo Fisher Scientific Leverages Integrated Solutions to Accelerate the Development of Biologic Therapeutics - BioSpace
Pharmacogenomics Market Detailed In New Research Report 2025 | - openPR.com
Thermo Fisher Scientific to invest $2 billion to expand US operation - Indian Pharma Post
ENCell and Thermo Fisher Scientific discuss expanded collaboration in cell and gene therapy field - koreabiomed.com
Competent Cells Market Detailed in New Research Report By 2032 | - openPR.com
Thermo Fisher Scientific Announces $2B Investment to Expand U.S. Operations - Thomasnet
Is Thermo Fisher Scientific Gaining or Losing Market Support? - Benzinga
Thermo Fisher commits $2B to US manufacturing - MedTech Dive
써모 피셔 사이언티픽 (TMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.53%
0.18%
자본화:
|
볼륨(24시간):